KBC Group
MYGN icon

KBC Group’s Myriad Genetics MYGN Stock Holding History

KBC Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,845
Closed -$52K – 1780
2025
Q1 		$52K Hold
5,845
– – ﹤0.01% 1781
2024
Q4 		$80K Buy
5,845
+3,334
+133% +$61.5K ﹤0.01% 1681
2024
Q3 		$69K Hold
2,511
– – ﹤0.01% 1533
2024
Q2 		$61K Hold
2,511
– – ﹤0.01% 1498
2024
Q1 		$54K Hold
2,511
– – ﹤0.01% 1510
2023
Q4 		$48K Hold
2,511
– – ﹤0.01% 1560
2023
Q3 		$40K Sell
2,511
-3,844
-60% -$73.1K ﹤0.01% 1626
2023
Q2 		$147K Hold
6,355
– – ﹤0.01% 1046
2023
Q1 		$148K Sell
6,355
-628
-9% -$12.8K ﹤0.01% 1072
2022
Q4 		$101K Hold
6,983
– – ﹤0.01% 1192
2022
Q3 		$133K Hold
6,983
– – ﹤0.01% 1082
2022
Q2 		$127K Buy
+6,983
New +$145K ﹤0.01% 1131
2022
Q1 		– Sell
-1,153
Closed -$32K – 1292
2021
Q4 		$32K Hold
1,153
– – ﹤0.01% 1271
2021
Q3 		$37K Sell
1,153
-30,251
-96% -$1M ﹤0.01% 1260
2021
Q2 		$960K Buy
31,404
+6,092
+24% +$176K ﹤0.01% 889
2021
Q1 		$770K Hold
25,312
– – ﹤0.01% 934
2020
Q4 		$2.75M Sell
25,312
-3,992
-14% -$64.5K ﹤0.01% 980
2020
Q3 		$382K Sell
29,304
-8,194
-22% -$104K ﹤0.01% 1011
2020
Q2 		$426K Sell
37,498
-5,986
-14% -$85K ﹤0.01% 1046
2020
Q1 		$622K Buy
43,484
+11,320
+35% +$239K 0.01% 820
2019
Q4 		$876K Hold
32,164
– – 0.01% 937
2019
Q3 		$921K Hold
32,164
– – 0.01% 896
2019
Q2 		$894K Hold
32,164
– – 0.01% 889
2019
Q1 		$1.07M Buy
32,164
+17,209
+115% +$524K 0.01% 845
2018
Q4 		$435K Sell
14,955
-27,764
-65% -$999K ﹤0.01% 957
2018
Q3 		$1.97M Buy
42,719
+31,532
+282% +$1.4M 0.01% 688
2018
Q2 		$418K Sell
11,187
-3,583
-24% -$121K ﹤0.01% 1028
2018
Q1 		$436K Buy
14,770
+7,577
+105% +$256K ﹤0.01% 981
2017
Q4 		$247K Buy
7,193
+1,962
+38% +$66.2K ﹤0.01% 1107
2017
Q3 		$189K Hold
5,231
– – ﹤0.01% 1128
2017
Q2 		$135K Hold
5,231
– – ﹤0.01% 1157
2017
Q1 		$100K Sell
5,231
-121,303
-96% -$2.15M ﹤0.01% 1261
2016
Q4 		$2.11M Buy
126,534
+9,103
+8% +$165K 0.02% 614
2016
Q3 		$2.42M Buy
117,431
+32,836
+39% +$833K 0.03% 529
2016
Q2 		$2.59M Buy
84,595
+8,841
+12% +$307K 0.04% 474
2016
Q1 		$2.83M Sell
75,754
-10,558
-12% -$398K 0.05% 414
2015
Q4 		$3.73M Buy
86,312
+18,524
+27% +$783K 0.07% 326
2015
Q3 		$2.54M Sell
67,788
-50,874
-43% -$1.81M 0.05% 390
2015
Q2 		$4.03M Sell
118,662
-9,882
-8% -$336K 0.05% 376
2015
Q1 		$4.55M Buy
128,544
+32,278
+34% +$1.16M 0.06% 332
2014
Q4 		$3.28M Buy
96,266
+71,470
+288% +$2.54M 0.04% 465
2014
Q3 		$956K Sell
24,796
-56,738
-70% -$2.12M 0.03% 530
2014
Q2 		$3.17M Buy
81,534
+48,775
+149% +$1.81M 0.04% 492
2014
Q1 		$1.12M Hold
32,759
– – 0.02% 635
2013
Q4 		$687K Buy
32,759
+3,986
+14% +$101K 0.01% 768
2013
Q3 		$677K Sell
28,773
-1,210
-4% -$34.4K 0.01% 761
2013
Q2 		$805K Buy
+29,983
New +$869K 0.01% 723

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

KBC Group's MYGN Position: Q2 2025 in Review

KBC Group sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 5,845 shares — an estimated $52K sold.

KBC Group first reported a position in MYGN in Q2 2013 and held it in 47 quarters. The position peaked at $4.55M in Q1 2015. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • KBC Group reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • KBC Group sold 5,845 Myriad Genetics shares in Q2 2025, an estimated $52K.
  • KBC Group first reported a position in Myriad Genetics in Q2 2013 and held it in 47 quarters.
  • KBC Group's Myriad Genetics position peaked at $4.55M in Q1 2015.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.